It is known that increasing replication via expanding the number of biological and or technical replicates analysed, increases overall experimental precision and statistical power. While the examples and data presented here will focus on the current multiplexed immunoassay experimental practice, where all samples are generally analysed in duplicate assays, the techniques presented are generic and apply to a wide variety of experimental designs and biological data types. The data presented is the fluorescence responses from screening for 14 analytes within 354 plasma samples, used in a clinical trial, collected from 177 patients and across 60 96-well plates. For plate or array based multiplexed immunoassay experiments the replicated design strategy halves the numbers of biological replicates that can be analysed per array or plate and therefore, essentially doubles the assay costs of the experiment. Here it’s shown that when the level of technical variance is less than the biological variances that for most types of immunoassay experiments, such as screening biological samples for the expression level of proteins, there is no benefit gained from using technical replicates when the number of biological replicates exceeds 20 samples. It is also presented that when the usual numbers of technical replicate assays, according to common practice, are replaced by unique biological replicate assays that the contribution to the observed assay variance from the biological variances decreases by 50%. Methods for determining the level of technical and biological variances in a sample are discussed, plus a new method is presented for determining the level of technical and biological variance within a sample.